Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases ...

DelveInsight's "LEQVIO Market Size, Forecast, and Market Insight Report" highlights the details around LEQVIO, which is a ...

GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

Q2 2025 Earnings Call Transcript May 12, 2025 Arrowhead Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $2 ...

Family history of heart disease means you need lower cholesterol numbers. Discover the specific targets that can save your ...

Q2 2025 Results Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor Relations ...

A Sip of Comfort… Or a Dose of Wellness? Let’s begin with a question you might’ve never asked seriously: when you pour ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs ... Journal of Medicine shows that obicetrapib significantly lowers LDL cholesterol in high-risk cardiovascular patients.

This might be due to lack of VLDL as precursor or, less likely, further upregulation of LDL receptors to keep up the inflow of cholesterol to the liver and other organs. In the plasma apheresis ...